Business
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Multiple Announcements of Clinical Data Results Anticipated in Q3 2025SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended June 30, 2025. Business Highlight
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"Multiple Announcements of Clinical Data Results Anticipated in Q3 2025","length":70,"tagName":"p"},{"type":"text","content":"SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended June 30, 2025.","length":421,"tagName":"p"},{"type":"text","content":"Business Highlights:","length":20,"tagName":"p"},{"type":"text","content":"ART26.12 –Advancing Toward Multi-dose Phase 1 Safety Study","length":58,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successfully completed a Phase 1 Single Ascending Dose (SAD) study in 49 healthy volunteers. Data confirmed positive safety results, with only mild, transient adverse events, no drug-related issues, and predictable, dose-linear pharmacokinetics. The wide therapeutic window supports dose titration flexibility and advancement to the next clinical stage.","length":353,"tagName":"p"}]},{"val":[{"type":"text","content":"Preparations are underway for a Multiple Ascending Dose (MAD) study to start in Q4 2025","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented new data at the British Pain Society Conference, validating the therapeutic potential of FABP inhibitors in osteoarthritis (OA). In a surgical rat model of OA, both single and repeat oral doses of ART26.12 significantly improved weight-bearing function, with effects sustained up to four weeks.","length":304,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced publication of a comprehensive review in Neurobiology of Disease, title...